MRI and CSF studies in the early diagnosis of Alzheimer's disease (Q30953178)

27 June 2017

MRI and CSF studies in the early diagnosis of Alzheimer's disease (English)

1 reference

magnetic resonance imaging

27 June 2017

0 references

0 references

3

Zinkowski R

0 references

author name string

de Leon MJ

1

1 reference

27 June 2017

DeSanti S

2

1 reference

27 June 2017

Mehta PD

4

1 reference

27 June 2017

Pratico D

5

1 reference

27 June 2017

Segal S

6

1 reference

27 June 2017

Clark C

7

1 reference

27 June 2017

Kerkman D

8

1 reference

27 June 2017

DeBernardis J

9

1 reference

27 June 2017

Li J

10

1 reference

27 June 2017

Lair L

11

1 reference

27 June 2017

Reisberg B

12

1 reference

27 June 2017

Tsui W

13

1 reference

27 June 2017

Rusinek H

14

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Journal of Internal Medicine

27 June 2017

1 reference

27 June 2017

256

1 reference

27 June 2017

205-223

1 reference

27 June 2017

3

1 reference

Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy

27 June 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Presence of abnormally phosphorylated Tau proteins in the entorhinal cortex of aged non-demented subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Sequence of Abeta-protein deposition in the human medial temporal lobe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Morphologically distinct plaque types differentially affect dendritic structure and organisation in the early and late stages of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Both total and phosphorylated tau are increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Longitudinal studies of regional cerebral metabolism in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Longitudinal stability of CSF tau levels in Alzheimer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Dynamics of brain-derived proteins in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Increased CSF F2-isoprostane concentration in probable AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Early marker for Alzheimer's disease: the atrophic hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Preclinical prediction of Alzheimer's disease using SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Rates of global and regional cerebral atrophy in AD and frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

MR imaging-based volume measurements of the hippocampal formation and anterior temporal lobe: validation studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

MRI volume of the amygdala: a reliable method allowing separation from the hippocampal formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Volumetric analysis of the pre-frontal regions: findings in aging and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

A two-year longitudinal study of cognitive function in normal aging and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Quantification of sub-femtomole amounts of Alzheimer amyloid beta peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Hippocampal atrophy in normal aging. An association with recent memory impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Hippocampal formation glucose metabolism and volume losses in MCI and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Hippocampal formation size predicts declining memory performance in normal aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01381.X

10.1111/J.1365-2796.2004.01381.X

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference